ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Gankyrin regulates cell signaling network.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 31 citations in OpenAlex.
- Synthesis and evaluation of 2,5-substituted pyrimidines as small-molecule gankyrin binders.Future medicinal chemistry · 2024Article
- Distinct ankyrin repeat subdomains control VAPYRIN locations and intracellular accommodation functions during arbuscular mycorrhizal symbiosis.Nature communications · 2022Article
- Biological effects and regulation of IGFBP5 in breast cancer.Frontiers in endocrinology · 2022Review
- Interaction between PSMD10 and GRP78 accelerates endoplasmic reticulum stress-mediated hepatic apoptosis induced by homocysteine.Gut pathogens · 2021Article
- LMX1B-associated gankyrin expression predicts poor prognosis in glioma patients.The Journal of international medical research · 2020Article
- LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells.OncoTargets and therapy · 2020Article
- Role of a 19S Proteasome Subunit- PSMD10International journal of stem cells · 2019Article
- Tumor Suppressor Down-Regulation Promotes Hepatocyte Proliferation: A New GANKster on the Block.Cellular and molecular gastroenterology and hepatology · 2018Article
- Gankyrin as a potential therapeutic target for cancer.Investigational new drugs · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gankyrin is an oncoprotein that facilitates the degradation of two key tumor suppressors, namely, Rb and p53. Although Gankyrin overexpression was identified in different carcinomas eventually and associated with poor prognosis, its function and mechanism remain not well understood. Recently, the signal transduction mechanisms of Gankyrin have been explored, which may provide new drug targets in tumors overexpressing Gankyrin. In this review, we summarize the significant signal transduction pathways regulated by Gankyrin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.